Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:57:14.934Z.
Calculation as of: 2026-10-06T20:57:14.934Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3ba604bfa669edc564cc368ab96d70220aa63ab01e3d3e65254ff63c7dd77471
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$137.80M
EBITDA Yield
N/A
TTM Avg
0.23%
3Y Avg
1.76%
5Y Avg
3.40%
Market Cap
$136.57M
EBITDA Yield
9.38%
TTM Avg
3.05%
3Y Avg
2.67%
5Y Avg
2.31%
Market Cap
$143.60M
EBITDA Yield
N/A
TTM Avg
2.27%
3Y Avg
2.27%
5Y Avg
2.27%
Market Cap
$143.84M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $139.04M | N/A | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.80M | N/A | 0.23% | 1.76% | 3.40% |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.67M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $136.57M | 9.38% | 3.05% | 2.67% | 2.31% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | N/A | 2.27% | 2.27% | 2.27% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
